An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

NCT02400476 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

563

Enrollment

INDUSTRY

Sponsor class

Conditions

Early Stage HER2+ Breast Cancer

Interventions

DRUG: Neratinib
DRUG: Loperamide
DRUG: Colestipol
DRUG: Budesonide

Sponsor

Puma Biotechnology, Inc.